This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 33 open trials.
In 125 locations
What is a Clinical Trial?
There are currently 33 open trials
- Isatuximab in combination with carfilzomib and dexamethasone for relapsed and/or refractory myeloma
- MGUS research study
- AZD4573 in relapsed or refractory myeloma
- Daratumumab vs. monitoring in high risk smouldering myeloma
- Selinexor for relapsed and refractory myeloma (BOSTON)
- NEOD001 in AL amyloidosis
- RO6870810 monotherapy and combination for relapsed and refractory myeloma patients
- Subcutaneous vs. intravenous daratumumab in relapsed and/or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Targeted radiotherapy for myeloma
- Pre-transplant exercise for myeloma patients (PREeMPT)
- Observational study of presentation, treatment and outcomes in myeloma patients (INSIGHT-MM)
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- Acupuncture for chemotherapy induced peripheral neuropathy in myeloma (ACUFOCIN)
- Ixazomib maintenance treatment for newly diagnosed myeloma patients
- Carfilzomib, daratumumab and dexamethasone for patients with relapsed and/or refractory myeloma (CANDOR trial)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- TAS-120 for refractory myeloma patients with FGF/FGFR abnormalities
- Carfilzomib, thalidomide and dexamethasone in relapsed AL amyloidosis (CATALYST trial)
- Isatuximab in combination with pomalidomide and dexamethasone (ICARIA-MM trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- MUK eleven (Reolysin trial)
- Myeloma XII (ACCoRd)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients
- Buparlisib in combination with bortezomib (BUBBLE trial)
- MUK eight
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK2857916 trial
- GSK525762 trial
Trial Title:
Isatuximab in combination with carfilzomib and dexamethasone for relapsed and/or refractory myeloma
Treatments:
Isatuximab
Carfilzomib (Kyprolis® )
Dexamethasone
Myeloma stage:
Relapsed, Refractory
Trial phase:
III
Summary:
The aim of this trial is to determine whether the addition of isatuximab to carfilzomib and dexamethasone prolongs progression free survival in relapsed and/or refractory myeloma patients, when compared to treatment with carfilzomib and dexamethasone alone.
Locations:
Derriford Hospital, Plymouth;
Leicester Royal Infirmary, Leicester
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have received between 1 and 3 prior treatments.
What's involved?:
What’s involved
Patients will be randomised to either received isatuximab, carfilzomib and dexamethasone, or carfilzomib and dexamethasone only.
Isatuximab is given intravenously (into the vein) on days 1, 8, 15 and 22 of the first 28-day cycle, and then on days 1 and 15 for subsequent cycles.
Carfilzomib is given intravenously on days 1, 2, 8, 9, 15 and 16 of each cycle.
Dexamethasone is given either intravenously, or taken by mouth, on days 1, 2, 8, 9, 15, 16, 22 and 23 of the 28-day cycle.
Treatment will continue until there are signs of disease progression. Patients will be required to attend out-patient clinics for regular check-ups and blood tests.
Clinical Information
(for Medical Professionals):
This is a randomised, open label, Phase III trial to determine the clinical benefit of isatuximab in combination with carfilzomib and dexamethasone in terms of prolonging progression-free survival in relapsed and/or refractory myeloma patients.
For more information, click here
Find out more: